Impax Gains Products In Watson Deal With FTC To Finalize Arrow Acquisition
By stepping in to help Watson Pharmaceuticals avoid antitrust problems in its acquisition of Arrow Group, Impax Laboratories has added cabergoline, the generic of Pfizer's Dostinex for Parkinson's Disease to its portfolio, as well as a pending ANDA for dronabinol, the generic of Solvay Pharmaceutical's Marinol for treating side effects of chemotherapy
You may also be interested in...
The required divestitures are quite significant relative to the size of the transaction: this is the second-largest divesture, but only the fifth-largest merger of generic firms.
Watson is eying partnerships to further expand branded and generics, but no major deals expected in near term, execs say.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011